CoreBone is developing a bioactive, coral-based bone graft material that provides the same qualities as organic material without the associated risks.

The Technology

CoreBone has developed a highly bioactive, strong bone graft material. The patented technology embeds bioactive minerals (e.g., silicium) into the skeleton of corals during their growth process to accelerate healing and provide better connectivity. It offers the same bonelike qualities as organic material (human/animal derived) without the associated risks.

The Advantages

CoreBone’s strictly controlled growing environment in its coral farm preserves the coral’s natural, bonelike properties. The coral-based material provides an optimal set of properties for improved bone grafts.

  • Strength: Structural strength from outset, similar to human bone
  • Bioactivity:
    • Bioactive materials that attract local stem cells to enhance growth, without the need for organic substances
    • Increased connectivity of new bone to existing bone and coral graft
  • 100% mineral based: No organic substances — no biological risk

Preclinical studies with CoreBone’s material demonstrated a high rate of bio-integration and connectivity with the host bone as compared with leading products in the market, as well as almost complete bone healing within two months.

The Founding Team

Ohad Schwartz Corebone

CoreBone CEO Ohad Schwartz (left) speaks with Scot Dodd of CR Current during a Trendlines Medical U.S. Road Show event in Michigan.

  • Ohad Schwartz, CEO & Co-Founder: Former CEO, Vaica Medical (medication management); CEO and co-founder, Aspect AI (MRI technologies); VP, TAMI 4
  • Prof. Itzhak Binderman, DMD, CTO & Co-Founder: Internationally recognized researcher in bone biology and dentistry; former head of Dental Dept. and Hard Tissue Laboratory, Sourasky Medical Center, Tel Aviv; School of Dental Medicine and Dept. of Bioengineering, Tel Aviv Univ.; senior researcher, Hospital for Special Surgery, New York


Stage: Business development
Founded: December 2011
Investors: The Trendlines Group, private investors, founders
IP: U.S. patent granted (method for producing bioactive coral bone graft substitutes) in early 2015; EU/Israel in National phase


  • October 2016: Received CE mark
  • Proved ability to grow bioactive material that produces bone
  • Completed multiple preclinical studies
  • Validated product qualities over competitive products

In the Media

Background & Market

Today, implants are used more and more in dental, orthopedic, and spine procedures. In many cases, bone is insufficient, and bone grafts stimulate the growth of new bone to support and anchor the implant. Most bone graft materials in the market are derived from human and animal bone and carry the risk of disease and rejection. Synthetic materials, a fast-growing segment, lack strength.

Bone grafts from human and animal origin are in decline due to their associated risks. The synthetic bioactive product share is growing as the market seeks alternatives. The global market for orthopedic bone graft substitutes is expected to reach $3.4 billion and the global dental bone graft market $1 billion ( by 2017.


CEO Ohad Schwartz interviewed on ILTV.

CEO Ohad Schwartz presents at the Trendlines Showcase.


Ohad Schwartz, CEO

CoreBone logo card